COVID - 19 Vaccination Update - Day 407 - Prevention is better than cure

Spread the Message

Read Time:1 Minute, 37 Second

Posted On: 26 FEB 2022 8:06 PM by PIB Delhi

India’s COVID-19 vaccination coverage hascrossed177.40 Crore (1,77,40,59,720) today. More than21lakh (21,41,821) Vaccine Doses have been administered till 7 pm today. More than1.99 Crore(1,99,62,729) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs	1^st Dose	10401480
	2^nd Dose	9965907
	Precaution Dose	4166909
FLWs	1^st Dose	18409341
	2^nd Dose	17439847
	Precaution Dose	6191330
Age Group 15-18 years	1^st Dose	54747973
	2^nd Dose	27260355
Age Group 18-44 years	1^st Dose	551674510
Age Group 18-44 years	2^nd Dose	443457581
Age Group 45-59 years	1^st Dose	202251597
Age Group 45-59 years	2^nd Dose	179982110
Over 60 years	1^st Dose	126392536
	2^nd Dose	112113754
	Precaution Dose	9604490
Cumulative 1^st dose administered		963877437
Cumulative 2^nd dose administered		790219554
Precaution Dose		19962729
Total		1774059720

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 26^thFebruary, 2022 (407^thDay)
HCWs	1^st Dose	79
	2^nd Dose	1242
	Precaution Dose	13104
FLWs	1^st Dose	131
	2^nd Dose	2302
	Precaution Dose	20887
Age Group 15-18 years	1^st Dose	113130
	2^nd Dose	606101
Age Group 18-44 years	1^st Dose	142585
Age Group 18-44 years	2^nd Dose	853526
Age Group 45-59 years	1^st Dose	20991
Age Group 45-59 years	2^nd Dose	178572
Over 60 years	1^st Dose	18698
	2^nd Dose	108961
	Precaution Dose	61512
Cumulative 1^st dose administered		295614
Cumulative 2^nd dose administered		1750704
Precaution Dose		95503
Total		2141821

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.